Compare GRNT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GRNT | CBIO |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.8M | 557.8M |
| IPO Year | 2022 | N/A |
| Metric | GRNT | CBIO |
|---|---|---|
| Price | $4.83 | $20.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 893.1K | 293.9K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 7.36% | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $450,306,000.00 | N/A |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $13.12 | $279.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $4.18 | $8.72 |
| 52 Week High | $6.59 | $27.41 |
| Indicator | GRNT | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 52.46 |
| Support Level | $4.18 | $10.83 |
| Resistance Level | $5.45 | $21.14 |
| Average True Range (ATR) | 0.22 | 2.10 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 9.96 | 58.83 |
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.